Cited 7 times in
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승업 | - |
dc.date.accessioned | 2023-03-21T07:34:06Z | - |
dc.date.available | 2023-03-21T07:34:06Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193442 | - |
dc.description.abstract | Background & aims: Antiviral treatment from hepatitis B envelope antigen (HBeAg)-positive status may attenuate the integration of hepatitis B virus DNA into the host genome causing hepatocellular carcinoma (HCC). We investigated the impact of HBeAg status at the onset of antiviral treatment on the risk of HCC. Methods: The incidence of HCC was evaluated in Korean patients with chronic hepatitis B who started entecavir or tenofovir in either HBeAg-positive or HBeAg-negative phase. The results in the Korean cohort were validated in a Caucasian PAGE-B cohort. Results: A total of 9143 Korean patients (mean age, 49.2 years) were included: 49.1% were HBeAg-positive and 49.2% had cirrhosis. During follow-up (median, 5.1 years), 916 patients (10.0%) developed HCC. Baseline HBeAg positivity was not associated with the risk of HCC in the entire cohort or cirrhotic subcohort. However, in the non-cirrhotic subcohort, HBeAg positivity was independently associated with a lower risk of HCC in multivariable (adjusted hazard ratio [aHR], 0.41; 95% confidence interval [CI], 0.26-0.66), propensity score-matching (aHR, 0.46; 95% CI, 0.28-0.76), and inverse probability weighting analyses (aHR, 0.44; 95% CI, 0.28-0.70). In the Caucasian cohort (n = 719; mean age, 51.8 years; HBeAg-positive, 20.3%; cirrhosis, 34.8%), HBeAg-positivity was not associated with the risk of HCC either in the entire cohort or cirrhotic subcohort. In the non-cirrhotic subcohort, none of the HBeAg-positive group developed HCC, although the difference failed to reach statistical significance (aHR, 0.21; 95% CI, 0.00-1.67). Conclusions: This multinational cohort study implies that HBeAg positivity at the onset of antiviral treatment seems to be an independent factor associated with a lower risk of HCC in patients with chronic hepatitis B without cirrhosis, but not in those with cirrhosis. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | W.B. Saunders | - |
dc.relation.isPartOf | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents / therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / etiology | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Hepatitis B Antigens / therapeutic use | - |
dc.subject.MESH | Hepatitis B e Antigens | - |
dc.subject.MESH | Hepatitis B virus / genetics | - |
dc.subject.MESH | Hepatitis B, Chronic* / complications | - |
dc.subject.MESH | Hepatitis B, Chronic* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis / complications | - |
dc.subject.MESH | Liver Neoplasms* / etiology | - |
dc.subject.MESH | Middle Aged | - |
dc.title | Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Heejoon Jang | - |
dc.contributor.googleauthor | Jun Sik Yoon | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Myoung-Jin Jang | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Hwi Young Kim | - |
dc.contributor.googleauthor | Sung Eun Kim | - |
dc.contributor.googleauthor | Dae Won Jun | - |
dc.contributor.googleauthor | Eileen L Yoon | - |
dc.contributor.googleauthor | Joo Hyun Sohn | - |
dc.contributor.googleauthor | Sang Bong Ahn | - |
dc.contributor.googleauthor | Jae-Jun Shim | - |
dc.contributor.googleauthor | Soung Won Jeong | - |
dc.contributor.googleauthor | Yong Kyun Cho | - |
dc.contributor.googleauthor | Hyoung Su Kim | - |
dc.contributor.googleauthor | Joon Yeul Nam | - |
dc.contributor.googleauthor | Yun Bin Lee | - |
dc.contributor.googleauthor | Yoon Jun Kim | - |
dc.contributor.googleauthor | Jung-Hwan Yoon | - |
dc.contributor.googleauthor | Fabien Zoulim | - |
dc.contributor.googleauthor | Pietro Lampertico | - |
dc.contributor.googleauthor | George N Dalekos | - |
dc.contributor.googleauthor | Ramazan Idilman | - |
dc.contributor.googleauthor | Vana Sypsa | - |
dc.contributor.googleauthor | Thomas Berg | - |
dc.contributor.googleauthor | Maria Buti | - |
dc.contributor.googleauthor | Jose Luis Calleja | - |
dc.contributor.googleauthor | John Goulis | - |
dc.contributor.googleauthor | Spilios Manolakopoulos | - |
dc.contributor.googleauthor | Harry LA Janssen | - |
dc.contributor.googleauthor | George V Papatheodoridis | - |
dc.contributor.googleauthor | Jeong-Hoon Lee | - |
dc.identifier.doi | 10.1016/j.cgh.2021.09.001 | - |
dc.contributor.localId | A00654 | - |
dc.relation.journalcode | J02981 | - |
dc.identifier.eissn | 1542-7714 | - |
dc.identifier.pmid | 34500103 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1542356521009356 | - |
dc.subject.keyword | Cumulative Incidence | - |
dc.subject.keyword | DNA | - |
dc.subject.keyword | Hepatitis B Virus | - |
dc.subject.keyword | Liver Cancer | - |
dc.subject.keyword | Neoplasm | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1343 | - |
dc.citation.endPage | 1353 | - |
dc.identifier.bibliographicCitation | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.20(6) : 1343-1353, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.